Wedbush Reiterates an 'Outperform' on Pharmacyclics (PCYC); Expect Ibrutinib to Dominate CLL Treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to Wedbush Reiterates an 'Outperform' on Pharmacyclics (PCYC); Expect Ibrutinib to Dominate CLL Treatment

Pharmacyclics, Inc. (PCYC) Posts Q4 Loss of 22c/Share

September 5, 2012 6:33 AM EDT

Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.49 million.

For earnings history and earnings-related data on Pharmacyclics, Inc. (PCYC) click here.... More